Abstract | BACKGROUND: METHODS: RESULTS: Median follow-up of 701 eligible patients was 4.1 years (0.4-6.5). Ninety patients (12.8%) died from breast cancer. Approximated subtype and chemotherapy response were significantly associated with BCSS and OS (P < 0.0001). BCSS and OS were highest in patients who achieved pathologic complete response (pCR) (P < 0.0001 and P < 0.0001, respectively).Five-year BCSS was highest in human epidermal growth factor receptor 2 (HER2)-positive disease [95.8%; 95% confidence interval (CI): 87.7-98.6], followed by hormone receptor-positive/HER2-negative (80.4%; 95% CI: 73.2-85.9) and lowest in triple-negative (TNBC) (74.8%; 95% CI: 66.6-81.2; P < 0.0001). Similar patterns were seen in OS.In TNBC (n = 174), 5-year BCSS was higher in patients with pCR versus residual disease (89.8%; 95% CI: 78.8-95.3 vs 65.8%; 95% CI: 54.5-74.9; P = 0.0013). In hormone receptor-positive/HER2-negative (n = 318) disease, BCSS was 100% in patients with pCR and 78.3% (95% CI: 70.4-84.3) in those with residual disease (P = 0.018). In HER2-positive disease (n = 204) there was no difference between pCR and residual disease (96.0%; 95% CI: 83.6-99.1 vs 95.8%; 95% CI: 81.4-99.1; P = 0.77). CONCLUSIONS:
|
Authors | Judy C Boughey, Karla V Ballman, Linda M McCall, Elizabeth A Mittendorf, William Fraser Symmans, Thomas B Julian, David Byrd, Kelly K Hunt |
Journal | Annals of surgery
(Ann Surg)
Vol. 266
Issue 4
Pg. 667-676
(10 2017)
ISSN: 1528-1140 [Electronic] United States |
PMID | 28657941
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Receptors, Estrogen
- Receptors, Progesterone
- ERBB2 protein, human
- Receptor, ErbB-2
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, mortality, pathology, surgery)
- Chemotherapy, Adjuvant
- Female
- Follow-Up Studies
- Humans
- Lymph Nodes
(pathology)
- Lymphatic Metastasis
- Neoadjuvant Therapy
- Neoplasm Recurrence, Local
- Receptor, ErbB-2
(analysis)
- Receptors, Estrogen
(analysis)
- Receptors, Progesterone
(analysis)
|